Henrik Zetterberg mainly investigates Pathology, Cerebrospinal fluid, Alzheimer's disease, Internal medicine and Dementia. His work carried out in the field of Pathology brings together such families of science as Biomarker and Multiple sclerosis. His Cerebrospinal fluid study combines topics in areas such as Tau protein, Csf biomarkers, Immunology and Amyloid.
In his research on the topic of Alzheimer's disease, Drug development is strongly related with Bioinformatics. His Internal medicine research incorporates elements of Gastroenterology, Endocrinology and Oncology. Disease covers Henrik Zetterberg research in Dementia.
His primary areas of investigation include Cerebrospinal fluid, Internal medicine, Disease, Pathology and Biomarker. In Cerebrospinal fluid, Henrik Zetterberg works on issues like Amyloid, which are connected to Amyloid precursor protein. His Dementia and Alzheimer's disease investigations are all subjects of Internal medicine research.
Henrik Zetterberg combines subjects such as Apolipoprotein E and Cohort with his study of Dementia. The concepts of his Disease study are interwoven with issues in Neuroimaging, Neuroscience and Clinical trial, Bioinformatics. His work on Multiple sclerosis expands to the thematically related Pathology.
Henrik Zetterberg spends much of his time researching Internal medicine, Disease, Cerebrospinal fluid, Biomarker and Dementia. His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology, Endocrinology, Neurology and Oncology. His Disease research is multidisciplinary, incorporating perspectives in Clinical trial and Neuroscience.
His study on Cerebrospinal fluid is covered under Pathology. Henrik Zetterberg has included themes like Prospective cohort study, Glial fibrillary acidic protein, Cohort and Atrophy in his Biomarker study. His research in Dementia intersects with topics in Alzheimer's disease and Apolipoprotein E.
The scientist’s investigation covers issues in Internal medicine, Disease, Biomarker, Cerebrospinal fluid and Dementia. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology, Neurology and Oncology. His research investigates the connection between Disease and topics such as Differential diagnosis that intersect with issues in Retrospective cohort study.
His Biomarker research is multidisciplinary, incorporating elements of Atrophy, PRNP, Neuropathology, Prospective cohort study and Cohort. His Cerebrospinal fluid research entails a greater understanding of Pathology. His study in Dementia is interdisciplinary in nature, drawing from both Alzheimer's disease, Apolipoprotein E, Amyloid beta and Amyloid.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Oskar Hansson;Oskar Hansson;Henrik Zetterberg;Peder Buchhave;Peder Buchhave;Elisabet Londos;Elisabet Londos.
Lancet Neurology (2006)
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
Kaj Blennow;Harald Hampel;Michael Weiner;Henrik Zetterberg.
Nature Reviews Neurology (2010)
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson;Henrik Zetterberg;Oskar Hansson;Niels Andreasen.
Defeating Alzheimer's disease and other dementias: a priority for European science and society
Bengt Winblad;Bengt Winblad;Philippe Amouyel;Sandrine Andrieu;Clive Ballard.
Lancet Neurology (2016)
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
Bob Olsson;Ronald Lautner;Ulf Andreasson;Annika Öhrfelt.
Lancet Neurology (2016)
Clearance systems in the brain—implications for Alzheimer disease
Jenna M. Tarasoff-Conway;Roxana O. Carare;Ricardo S. Osorio;Lidia Glodzik.
Nature Reviews Neurology (2015)
Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lars Lannfelt;Kaj Blennow;Henrik Zetterberg;Stellan Batsman.
Lancet Neurology (2008)
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Harald Hampel;Richard Frank;Karl Broich;Stefan J. Teipel.
Nature Reviews Drug Discovery (2010)
Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
Peder Buchhave;Lennart Minthon;Henrik Zetterberg;Åsa K. Wallin.
Archives of General Psychiatry (2012)
The Neuropathology and Neurobiology of Traumatic Brain Injury
Kaj Blennow;John Hardy;Henrik Zetterberg;Henrik Zetterberg.
Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking h-index is inferred from publications deemed to belong to the considered discipline.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: